Peter Grebow, PhD held several key senior management positions at Cephalon Inc., a biopharmaceutical company, before retiring in 2011. He joined Cephalon in January 1991, where he served in several positions including Senior Vice President, Worldwide Business Development, Senior Vice President, Drug Development, Executive Vice President of Technical Operations, and most recently Executive Vice President of Cephalon Ventures.
Prior to joining Cephalon, Dr. Grebow served as the Vice President, Drug Development for Rorer Central Research, a division of Rhone-Poulenc Rorer Pharmaceuticals Inc., from 1988 to 1990. He is President and founder of P.E. Grebow Consulting, Inc., which he formed in 2011. He served as Executive Vice President of Research and Development at Eagle Pharmaceuticals, Inc. from 2013 to 2017. In addition, Dr. Grebow served as a director for Optimer Pharmaceuticals, Inc. from 2009 until 2013, GenSpera, Inc. from 2012 to 2018, Complexa, Inc. from 2011 to 2017. He has served as a director of Q Therapeutics, Inc. since December of 2011, and as a director of Molecular Targeting Technologies, Inc. since December, 2019.
He received his undergraduate degree from Cornell University, a Master’s of Science in Chemistry from Rutgers University, and a PhD in Physical Biochemistry from the University of California, Santa Barbara.